LEUVEN: Augustine Therapeutics NV announced the successful completion of its €77.7 million ($84.8 million) Series A funding round. Co-led by Novo Holdings and Jeito Capital, the financing also included investments from Asabys Partners, Eli Lilly, AdBio Partners, V-Bio Ventures, and others.
Augustine focuses on developing therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases by selectively inhibiting the HDAC6 enzyme. The funds will advance its lead candidate, AGT-100216, into Phase I/II clinical trials for Charcot-Marie-Tooth disease (CMT) and support additional programs targeting neurodegenerative and cardio-metabolic disorders.
CEO Gerhard Koenig, PhD, praised the support from investors, emphasizing Augustine’s innovative approach to HDAC6 inhibition. Novo Holdings and Jeito Capital representatives have joined the company’s board.